Targeting the JAK–STAT Signaling Axis in Cancer

Dear Colleagues,

Cancers represent one of the leading causes of death worldwide, afflicting every organ system and impacting all stages of the life course. A myriad of genetic, epigenetic and other causes have been identified that complicates the development of strategies for treatment. However, many of these underlying causes utilize common mechanisms to promote cancer formation and progression. These include the Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling axis, which contributes to a wide range of hematologic malignancies and solid tumors. As such, this pathway represents an attractive target for therapy across a broad range of cancers.

We are pleased to invite you to submit articles including to this Special Issue, including in the form of research papers and reviews.

Consistent with the scope and aims of Cancers, this Special Issue ‘Targeting the JAK–STAT Signaling Axis in Cancer’ aims to provide basic, translational and clinical perspectives on the JAK–STAT pathway across a variety of cancer types, including well-executed studies showing meaningful but negative results. In this Special Issue, original high-quality research articles and reviews are welcome. Research areas may include (but are not limited to) mechanistic and etiological investigations, therapeutic development and testing in both preclinical and clinical settings.

I look forward to receiving your contributions.

Prof. Dr. Alister C. Ward
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.